Opinion

Video

Evolution of Testing Strategies for ESR1

Author(s):

Virginia G. Kaklamani, MD, DSc,Heather McArthur, MD, MPH

The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer.

  1. What are the challenges and limitations of current strategies to overcome or delay the emergence of ESR1 mutations and endocrine resistance?
    • Based on the prevalence and impact of ESR1 mutations, what are the key unmet needs in treating this patient population?
Related Videos
Alexis LeVee, MD
2 expert is featured in this series.
4 experts are featured in this series.
2 experts in this video
2 experts in this video
Related Content
Kelly K. Hunt, MD, FACS, FSSO, of MD Anderson Cancer Center
January 3rd 2025

One Surgeon’s Spirit and Brilliance Lift a Whole Community

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Felipe Batalini, MD, of Mayo Clinic
December 26th 2024

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Lasofoxifene in Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 19th 2024

Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
December 17th 2024

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS